H
0.870
-0.01 (-0.57%)
| Previous Close | 0.875 |
| Open | 0.870 |
| Volume | 2,928 |
| Avg. Volume (3M) | 27,600 |
| Market Cap | 10,727,366 |
| Price / Sales | 0.980 |
| Price / Book | 0.500 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Operating Margin (TTM) | -885.28% |
| Diluted EPS (TTM) | -5.85 |
| Quarterly Revenue Growth (YOY) | -94.50% |
| Total Debt/Equity (MRQ) | 1.75% |
| Current Ratio (MRQ) | 3.61 |
| Operating Cash Flow (TTM) | -52.77 M |
| Levered Free Cash Flow (TTM) | -32.81 M |
| Return on Assets (TTM) | -45.20% |
| Return on Equity (TTM) | -105.79% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | HOOKIPA Pharma Inc. | Mixed | Mixed |
AIStockmoo Score
-0.3
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | -0.33 |
|
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 19.29% |
| % Held by Institutions | 34.18% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |